Xanthines and Phosphodiesterase Inhibitors

Area of Science:

• Pharmacology
• Respiratory Medicine

Background:

• Theophylline, an orally acting xanthine, has been a long-standing treatment for asthma and COPD since 1937.
• Xanthines are now often third-line therapy due to a narrow therapeutic window and drug-drug interactions.
• Lower doses of theophylline exhibit anti-inflammatory effects relevant to respiratory diseases.

Purpose of the Study:

• To explore the anti-inflammatory mechanisms of theophylline in respiratory diseases.
• To discuss the role of xanthines in current asthma and COPD management.
• To compare theophylline with newer agents like roflumilast.

Main Methods:

• Review of existing literature on theophylline's pharmacology and clinical use.
• Discussion of proposed molecular mechanisms of action.
• Comparison with other xanthines (doxofylline, bamifylline) and PDE4 inhibitors (roflumilast).

Main Results:

• Theophylline's anti-inflammatory actions are relevant for asthma and COPD treatment.
• Potential mechanisms include PDE inhibition, phosphoinositide 3-kinase inhibition, adenosine receptor antagonism, and HDAC activation.
• Xanthines provide clinical benefit in glucocorticosteroid-refractory patients and are essential for disease management.

Conclusions:

• Theophylline and related xanthines remain important in managing asthma and COPD, especially in refractory cases.
• Understanding their mechanisms is key to optimizing their use.
• Newer agents like roflumilast show promise but have dose-limiting side effects.